BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

Research output: Contribution to journalArticle

168 Scopus citations
Original languageEnglish (US)
Pages (from-to)428-442
Number of pages15
JournalCancer Cell
Volume26
Issue number3
DOIs
StatePublished - 2014

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Oncology

Cite this

Zabriskie, M. S., Eide, C. A., Tantravahi, S. K., Vellore, N. A., Estrada, J., Nicolini, F. E., Khoury, H. J., Larson, R. A., Konopleva, M., Cortes, J. E., Kantarjian, H., Jabbour, E. J., Kornblau, S. M., Lipton, J. H., Rea, D., Stenke, L., Barbany, G., Lange, T., Hernández-Boluda, J. C., ... O'Hare, T. (2014). BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. Cancer Cell, 26(3), 428-442. https://doi.org/10.1016/j.ccr.2014.07.006